Phenyl Derivatives as EP2 and EP4 Receptor Antagonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, particularly those involving immune modulation, face challenges in effectively targeting the tumor microenvironment due to the immuno-suppressive effects of PGE2 signaling through EP2 and EP4 receptors, which promote tumor growth and immune evasion.
Innovation Solution
Development of phenyl derivatives and pyrimidine compounds that act as dual antagonists of the EP2 and EP4 receptors, modulating the immune response to reactivate the immune system within tumors, potentially used in combination with chemotherapy, radiotherapy, or immunotherapy for various cancer types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If COX-2 inhibitors are used to reduce PGE2 production, then tumor growth and metastasis are inhibited, but cardiovascular side effects occur
Solution Approach 1:
The patent segments the COX-2 inhibition function into selective EP2 and EP4 receptor antagonism. Instead of broadly inhibiting COX-2 enzyme activity (which affects all prostanoid production), the invention directly targets only the EP2 and EP4 receptors that mediate tumor-promoting and immunosuppressive effects of PGE2, thereby preserving cardiovascular protective prostanoids and reducing cardiovascular side effects while maintaining anti-tumor efficacy
Solution Approach 2:
The patent introduces EP2 and EP4 receptor antagonists as intermediary agents that specifically block the harmful signaling pathways of PGE2 without affecting PGE2 production. These antagonists act as selective mediators that intercept PGE2 signaling only at the receptors responsible for tumor progression and immune suppression, leaving other physiological functions intact
2Reliability
If PGE2 signaling is blocked to enhance immune response, then immune evasion is reduced, but tumor growth promotion via other pathways may persist
Solution Approach 1:
The patent merges the blocking of both EP2 and EP4 receptors into a single therapeutic strategy using dual antagonists or combination therapy. This combined approach simultaneously addresses multiple PGE2-mediated pathways including immune suppression, angiogenesis, and direct tumor cell survival signals, preventing tumor adaptation through alternative single-receptor pathways
3Reliability
If COX-2 inhibitors are used broadly, then all prostanoid production is reduced, but non-selective inhibition causes off-target effects
Solution Approach 1:
The patent applies local quality by directing inhibition specifically at EP2 and EP4 receptors rather than broadly inhibiting all COX-2 derived prostanoids. This localized approach ensures that only the specific receptors mediating tumor progression and immune suppression are blocked, while other prostanoids with protective or neutral functions (such as those acting on TP, IP, or FP receptors) remain unaffected, thereby eliminating off-target effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds can inhibit tumor growth and metastasis by blocking PGE2 signaling, enhancing the immune response against cancer cells, and may offer a more targeted approach to cancer treatment with reduced cardiovascular side effects compared to COX-2 inhibitors.
Implementation Method 1
Development of phenyl derivatives and pyrimidine compounds that act as dual antagonists of the EP2 and EP4 receptors, modulating the immune response to reactivate the immune system within tumors
Implementation Method 2
modulating an immune response comprising a reactivation of the immune system in the tumor
Data Source
AI summary
The present invention relates to phenyl derivatives of formula (I)wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.